Patents Assigned to Ignyta, Inc.
-
Publication number: 20220257592Abstract: Provided herein are methods of treating cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of entrectinib wherein the patient has impaired hepatic function and methods of managing adverse reactions of administration of entrectinib in a patient.Type: ApplicationFiled: February 1, 2022Publication date: August 18, 2022Applicants: HOFFMANN-LA ROCHE INC., IGNYTA, INC., GENENTECH, INC.Inventors: Georgina Meneses-Lorente, Edna Chow Maneval, Pratik S. Multani, Susan Diane Eng, Sergio Rene Ley Acosta
-
Patent number: 11253515Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.Type: GrantFiled: January 17, 2020Date of Patent: February 22, 2022Assignee: Ignyta, Inc.Inventors: Daniel Codallos, Jr., Robert Orr, Ching-Yuan Li, Valerie Denise Start
-
Publication number: 20210322439Abstract: Disclosed herein are compositions and methods for treating cancer patients who have been previously treated with one or more chemotherapeutic agents and have developed at least partial resistance to such chemotherapeutic agents. Also disclosed are methods for selecting compounds suitable for treatment of cancer in a patient who has become resistant to an inhibitor of a receptor tyrosine kinase (RTK).Type: ApplicationFiled: June 23, 2021Publication date: October 21, 2021Applicant: IGNYTA, INC.Inventor: Ge Wei
-
Patent number: 11007191Abstract: The present disclosure relates to pharmaceutical compositions comprising N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide and a polymer, dosage forms comprising the formulation and methods of treating subjects having cancer.Type: GrantFiled: April 14, 2020Date of Patent: May 18, 2021Assignee: IGNYTA, INC.Inventors: Robert Orr, Kathryn Emily Colombo Pugh, Matthew Jarud Shaffer, Brent Antone Uhrig, Edward Dennis Lachapelle, Charlie Michael McLaughlin
-
Publication number: 20210113555Abstract: Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.Type: ApplicationFiled: December 9, 2020Publication date: April 22, 2021Applicant: IGNYTA, INC.Inventors: Gang Li, Ge Wei, Zachary D. Hornby, Jonathan Ee-ren Lim
-
Patent number: 10869864Abstract: Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.Type: GrantFiled: December 15, 2016Date of Patent: December 22, 2020Assignee: IGNYTA, INC.Inventors: Gang Li, Ge Wei, Zachary D. Hornby, Jonathan Ee-ren Lim
-
Patent number: 10799503Abstract: Disclosed herein are methods of treating cancer in a subject, wherein the subject is known to possess at least one genetic alteration in RET, comprising administering to the subject a therapeutically effective amount of N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N?-[5-(2,2,2-trifluoro-1, 1-dimethylethyl)-3-isoxazolyl]-urea, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 29, 2017Date of Patent: October 13, 2020Assignee: IGNYTA, INC.Inventors: Jonathan Ee-Ren Lim, Pratik S. Multani, Richard Landin, Rupal Patel, Jennifer Wright Oliver
-
Patent number: 10682348Abstract: Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.Type: GrantFiled: January 16, 2019Date of Patent: June 16, 2020Assignees: IGNYTA, INC., NERVIANO MEDICAL SCIENCES S.r.L.Inventors: Jonathan Lim, Elena Ardini, Maria Menichincheri
-
Publication number: 20200163892Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.Type: ApplicationFiled: January 17, 2020Publication date: May 28, 2020Applicant: IGNYTA, INC.Inventors: Daniel CODALLOS, JR., Robert ORR, Ching-Yuan LI, Valerie Denise START
-
Publication number: 20200069688Abstract: Disclosed herein are methods of treating cancer in a subject, wherein the subject is known to possess at least one genetic alteration in RET, comprising administering to the subject a therapeutically effective amount of N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N?-[5-(2,2,2-trifluoro-1, 1-dimethylethyl)-3-isoxazolyl]-urea, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 29, 2017Publication date: March 5, 2020Applicant: IGNYTA, INC.Inventors: Jonathan Ee-Ren Lim, Pratik S. Multani, Richard Landin, Rupal A. Patel, Jennifer Wright Oliver
-
Patent number: 10561651Abstract: Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.Type: GrantFiled: July 31, 2018Date of Patent: February 18, 2020Assignees: IGNYTA, INC., NERVIANO MEDICAL SCIENCES, S.R.L.Inventors: Jonathan Lim, Elena Ardini, Maria Menichincheri
-
Patent number: 10398693Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.Type: GrantFiled: July 18, 2018Date of Patent: September 3, 2019Assignee: IGNYTA, INC.Inventors: Daniel Codallos, Jr., Robert Orr, Ching-Yuan Li, Valerie Denise Start
-
Publication number: 20190224200Abstract: The present disclosure relates to certain combinations for the treatment of cancer in a subject, comprising one or more inhibitors of Tyro3, Axl, Mer, or c-Met, together with one or more compounds that are inhibitors of programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1).Type: ApplicationFiled: August 22, 2017Publication date: July 25, 2019Applicant: IGNYTA, INC.Inventors: Eric Santos MARTIN, Yumi YOKOYAMA
-
Patent number: 10357490Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.Type: GrantFiled: August 1, 2018Date of Patent: July 23, 2019Assignee: IGNYTA, INC.Inventors: Zachary Dolph Hornby, Gang Li, David Wesley Anderson, Garrett M Brodeur, Radhika Iyer
-
Publication number: 20190185567Abstract: The present disclosure relates to certain combinations for the treatment of cancer in a subject, comprising one or more inhibitors of Tyro3, Axl, Mer, or c-Met, together with one or more compounds that are inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).Type: ApplicationFiled: July 28, 2017Publication date: June 20, 2019Applicant: IGNYTA, INC.Inventors: Eric Santos MARTIN, Yumi YOKOYAMA
-
Publication number: 20190151317Abstract: This application describes the use of the compound or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed.Type: ApplicationFiled: June 26, 2018Publication date: May 23, 2019Applicant: IGNYTA, INC.Inventors: Thelma S. ANGELES, Mark A. ATOR, Mangeng M. CHENG, Bruce D. DORSEY, Robert L. HUDKINS, Bruce A. RUGGERI
-
Patent number: 10231965Abstract: Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.Type: GrantFiled: February 17, 2015Date of Patent: March 19, 2019Assignees: IGNYTA, INC., NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Jonathan Lim, Elena Ardini, Maria Menichincheri
-
Publication number: 20190070173Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.Type: ApplicationFiled: August 1, 2018Publication date: March 7, 2019Applicant: IGNYTA, INC.Inventors: Zachary Dolph HORNBY, Gang LI, David Wesley ANDERSON, Garrett M. BRODEUR, Radhika IYER
-
Publication number: 20190022089Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.Type: ApplicationFiled: July 18, 2018Publication date: January 24, 2019Applicant: Ignyta, Inc.Inventors: Daniel CODALLOS, JR., Robert ORR, Ching-Yuan LI, Valerie Denise START
-
Publication number: 20190000840Abstract: Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.Type: ApplicationFiled: December 15, 2016Publication date: January 3, 2019Applicant: IGNYTA, INC.Inventors: Gang LI, Ge WEI, Zachary D. HORNBY, Jonathan Ee-ren LIM
